KALAGeneral
▼ -27.8%on this news· ran to -46% by day 3
KALA BIO Announces Reverse Stock Split
KALA BIO, Inc. has announced a reverse stock split at a ratio of 1-for-50, effective May 8, 2026. The split is designed to reduce the total number of outstanding shares from approximately 929 million to about 18.5 million. This decision follows stockholder approval granting the Board discretion over the split. Shareholders will not need to exchange certificates as adjustments will be made automatically by brokers.
Read more →KALAGeneral
▼ -27.8%on this news· ran to -46% by day 3
KALA BIO Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on
KALA BIO, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-50, effective May 8, 2026. This action will reduce the total number of outstanding shares from approximately 929 million to about 18.6 million. The company's common stock will continue to be listed on the Nasdaq under the ticker KALA. Stockholders are advised that they will not require new certificates, as shares held via brokerage accounts will automatically adjust to the new ratio.
Read more →KALAFDA Updates
▼ -7.4%on this news· ran to -32% by day 3
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
Kala Bio has welcomed a transformative Executive Order signed by President Trump, which prioritizes the review of psychedelic compounds and reduces research restrictions. The initiative also establishes improved patient access pathways under the Right to Try Act and allocates $50 million for psychedelic therapy research. KALA is uniquely positioned to leverage these regulatory advancements through its partnership with Red Light Holland Corp., enhancing the development of psychedelic therapies supported by its AI platform, Researgency.ai. This policy shift marks a significant transition for the integration of psychedelic medicine into mainstream healthcare.
Read more →KALAGeneral
▼ -5.8%on this news
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Kala Bio Inc. has announced the appointment of Dr. Saeid Babaei as Senior Scientific Advisor. His role will focus on the evaluation of Kala's clinical assets using AI-enabled analytics and securing data integration. This collaboration aims to enhance the scientific and commercial value of existing assets, particularly in the MSC secretome space, which is projected to grow significantly in the coming years. The company plans a thorough review of its datasets to identify potential developments and indications for future growth.
Read more →KALAGeneral
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
KALA BIO has launched the Bionic Intelligence Research Agent (BIRA), an autonomous AI solution for the biotechnology sector. This deployment marks a significant step in KALA's transformation into an AI infrastructure partner. BIRA operates within secure environments, ensuring data sovereignty and compliance with pharmaceutical standards. The platform is designed to enhance research capabilities while maintaining enterprise-grade security.
Read more →KALAGeneral
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate
Red Light Holland has partnered with Kala Bio to utilize its Researgency.ai platform for the clinical development of PEX010, a botanical psilocybin drug candidate. This collaboration aims to enhance research planning and protocol optimization as PEX010 progresses through clinical trials. The drug candidate is being studied for various mental health conditions and has received authorization for clinical trials from both Health Canada and the FDA.
Read more →KALAGeneral
▲ +24.2%on this news
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
KALA BIO is set to launch its first commercial AI product through its Researgency.ai platform within the next 14 days. This marks a significant transition from a clinical-stage biotech to a dual-engine growth model that combines its drug pipeline with AI technology for the healthcare industry. The company aims to streamline operations in biotech and pharmaceuticals, addressing complex and time-sensitive processes. However, it faces challenges related to the efficacy of AI technologies and market competition.
Read more →KALAGeneral
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”
KALA BIO has launched a strategic initiative to develop an on-premises AI infrastructure platform called Researgency, aimed at serving the biotechnology industry. This platform allows biotech companies to deploy AI capabilities while retaining control of their proprietary data. KALA will initially use the platform for its own datasets before offering it to external clients. The company believes this approach addresses a significant technology adoption gap in the biotech sector.
Read more →KALAGeneral
KALA BIO Settles Approximately $10.6 million of Debt
KALA BIO, Inc. has completed a significant loan settlement with Oxford Finance, resolving approximately $10.6 million of debt obligations. This settlement included a $2 million payment made by KALA, which satisfied both the Settlement Agreement and the underlying Loan Agreement. The CEO highlighted that this milestone enhances the company's strategic flexibility by alleviating financial burdens, creating a more promising outlook for KALA's future. Additionally, KALA has granted stock awards to new employees as part of its ongoing growth initiatives.
Read more →KALAGeneral
▼ -6.9%on this news· ran to -23% by day 3
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
KALA BIO, Inc. has announced the successful closing of a $10 million registered direct offering of common stock priced at-the-market under Nasdaq rules. The offering involved 10 million shares sold at $1.00 each, with proceeds intended for debt repayment and corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent.
Read more →KALAGeneral
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
KALA BIO, Inc. announced a registered direct offering of 10,000,000 shares of common stock priced at $1.00 per share, expected to raise approximately $10 million. The proceeds will be utilized to repay specific debts and for general corporate purposes. The offering is set to close around December 5, 2025, pending customary conditions. This initiative is conducted under SEC regulations, ensuring it adheres to legal standards.
Read more →KALAGeneral
▲ +37.7%on this newsshared move
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
KALA BIO has entered a $6 million securities purchase agreement with investor David E. Lazar, who will also serve as the new CEO. This investment comes after the company's Phase 2b trial for KPI-012 failed to meet its primary endpoint. Despite this setback, KALA plans to continue evaluating its therapeutic candidates and explore strategic options for growth.
Read more →KALAPhases
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
KALA BIO announced that its CHASE Phase 2b clinical trial for KPI-012 did not meet its primary endpoint of complete healing of persistent corneal epithelial defect (PCED). The trial also failed to achieve statistical significance for secondary endpoints. As a result, KALA plans to discontinue the development of KPI-012 and explore strategic options to preserve cash.
Read more →KALAConferences/Events
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
KALA BIO, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025. The management team will also hold one-on-one meetings with investors. KALA is focused on developing therapies for rare eye diseases and has received FDA designations for its lead product candidate, KPI-012.
Read more →KALAGeneral
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
KALA BIO has appointed Todd Bazemore as President and CEO, following his interim role since February 2025. Bazemore's leadership is anticipated to guide the company through a pivotal phase as it approaches a key data readout for its KPI-012 treatment in a Phase 2b trial. The company aims to transition towards commercialization of its innovative therapies for rare eye diseases.
Read more →KALAPhases
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
KALA BIO reported its second quarter 2025 financial results, highlighting the completion of patient enrollment in the Phase 2b CHASE trial for KPI-012 targeting Persistent Corneal Epithelial Defect (PCED). The company anticipates topline data by the end of September 2025, which could support a Biologics License Application to the FDA. KALA's cash resources are sufficient to fund operations into the first quarter of 2026.
Read more →KALAConferences/Events
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
KALA BIO, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. The presentation will include a panel discussion on novel treatments for front-of-the-eye indications. KALA's lead product candidate, KPI-012, is in clinical development for persistent corneal epithelial defect.
Read more →KALAPhases
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
KALA BIO, Inc. has successfully completed patient enrollment in the CHASE Phase 2b clinical trial assessing KPI-012 for treating persistent corneal epithelial defect (PCED). The trial involves 79 patients across 37 sites in the U.S. and Latin America, aiming to evaluate the efficacy and safety of the treatment. With topline results expected by the end of Q3 2025, the company anticipates that positive outcomes could pave the way for a Biologics License Application (BLA) submission. KPI-012 has also received Orphan Drug and Fast Track designations from the FDA, highlighting its potential in addressing a significant medical need.
Read more →KALAConferences/Events
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
KALA BIO, Inc. will host a virtual Key Opinion Leader event on July 16, 2025, to discuss KPI-012, a treatment for persistent corneal epithelial defect (PCED). The event will cover the disease overview, patient journey, and insights from clinical trials. KALA's CEO will also discuss the commercial potential of KPI-012.
Read more →KALAConferences/Events
KALA BIO to Present at Jefferies Global Healthcare Conference
KALA BIO, Inc. will present at the Jefferies Global Healthcare Conference on June 5, 2025. The presentation will highlight the company's innovative therapies for rare eye diseases, particularly its lead product candidate, KPI-012. Management will also be available for one-on-one meetings during the event.
Read more →KALAPhases
▼ -6%on this news
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update -- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipate
KALA BIO, Inc. has announced its first-quarter financial results for 2025, reporting a cash position of $42.2 million expected to sustain operations into Q1 2026. The company is focused on advancing its KPI-012 candidate in the ongoing Phase 2b CHASE trial, with topline data anticipated in the third quarter of 2025. KPI-012 is aimed at treating Persistent Corneal Epithelial Defect (PCED) and could potentially serve as the first therapy to address all underlying issues of this condition.
Read more →KALAPhases
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update -- Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED)- --Co
KALA BIO, Inc. revealed its financial results for the fourth quarter and full year of 2024, highlighting its ongoing Phase 2b CHASE trial for KPI-012 in Persistent Corneal Epithelial Defect (PCED), which has randomized 87 patients to date. The company completed a private placement financing of $10.75 million, boosting its cash reserves to $51.2 million, projected to fund operations into early 2026. With topline data expected in the third quarter of 2025, KALA remains optimistic about the potential impact of KPI-012 on treating PCED.
Read more →KALAConferences/Events
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
KALA BIO, a clinical-stage biopharmaceutical company focused on eye diseases, announced plans to present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025. The presentation will include a discussion about KALA's lead product candidate, KPI-012, which is aimed at treating persistent corneal epithelial defect. The event highlights KALA's continued engagement with the investment community and its innovative approach to eye health. Management will also conduct one-on-one meetings with interested parties following the presentation.
Read more →KALAGeneral
KALA BIO Announces Chief Executive Officer Transition
KALA BIO, Inc. announced a leadership transition as CEO Mark Iwicki resigned, appointing Todd Bazemore, the President and COO, as interim CEO. Iwicki will remain with the company as Chair of the Board. Bazemore, who has been with KALA since December 2021, expressed enthusiasm for building on the company’s foundation and advancing the development of KPI-012, which is undergoing a Phase 2b clinical trial for persistent corneal epithelial defect. The company aims to deliver innovative therapies for rare eye diseases.
Read more →KALAGeneral
KALA BIO Announces $10,750,000 Private Placement
KALA BIO, Inc. announced a private placement agreement to raise approximately $10.75 million through the sale of common stock and convertible preferred stock. This funding will support the company's ongoing clinical trials, specifically for KPI-012, aimed at treating persistent corneal epithelial defect. With over 80% enrollment in the Phase 2b CHASE trial, KALA expects to report topline data by the second quarter of 2025. The placement's closing is subject to customary conditions and has attracted both new and existing institutional investors.
Read more →KALAConferences/Events
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
KALA BIO, Inc. will present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 4, 2024. Dr. Kim Brazzell, the company's Head of R&D, will lead the presentation, which will be available for streaming on KALA's website. In addition to the presentation, management will be available for one-on-one meetings. KALA is focused on developing therapies for rare eye diseases, with its lead candidate KPI-012 currently in clinical development for a rare ocular condition.
Read more →KALAPhases
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update -- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expecte
KALA BIO, Inc. reported its third quarter 2024 financial results and provided an update on its corporate activities, notably ongoing patient enrollment in the Phase 2b CHASE trial for KPI-012, targeting Persistent Corneal Epithelial Defect. The company anticipates topline results in the second quarter of 2025, aiming to establish KPI-012 as a first-in-class treatment option. Additionally, KALA's cash reserves have decreased, yet they expect to fund operations into late 2025, while also expanding clinical trial sites in Latin America.
Read more →KALAConferences/Events
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
KALA BIO, Inc. will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. Kim Brazzell, Ph.D., the company's Head of R&D and Chief Medical Officer, will lead the presentation, which will be available online. The company specializes in developing therapies for severe eye diseases, notably their lead candidate KPI-012 aimed at treating persistent corneal epithelial defects.
Read more →KALAGeneral
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update -- Closed $12.5 million private placement financing led by SR One with participation from ADAR1 Capital Management and another life sci
KALA BIO has reported its financial results for the second quarter of 2024, highlighting a successful $12.5 million private placement financing and a cash position of $54.2 million. The company is advancing its lead candidate, KPI-012, for the treatment of Persistent Corneal Epithelial Defect (PCED), with topline data from its Phase 2b CHASE trial expected in Q1 2025. KALA also seeks to leverage its MSC-S platform for innovative therapies in ocular diseases, targeting other indications including inherited retinal diseases. The financial resources are anticipated to sustain operations into the fourth quarter of 2025, supporting ongoing clinical developments.
Read more →KALAGeneral
KALA BIO Announces $12,500,000 Private Placement
KALA BIO, Inc. has announced a private placement agreement with institutional accredited investors, securing approximately $12.5 million in gross proceeds. The company intends to utilize these funds to further the clinical development of KPI-012, a treatment for persistent corneal epithelial defect. The securities sold in the placement include common stock and Series H Preferred Stock, with the closing expected on June 28, 2024, subject to standard conditions. KALA's lead product candidate has garnered FDA designations to expedite its development process.
Read more →KALAPhases
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update -- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- Evaluating opportu
KALA BIO, Inc. reported its financial results for the first quarter of 2024, highlighting ongoing patient enrollment in the Phase 2b CHASE trial for KPI-012 aimed at treating persistent corneal epithelial defect (PCED). The company targets topline data by the end of 2024, representing a step towards pivotal trial requirements for a BLA submission. KALA's cash position stands at $48.5 million, allowing operational funding into the third quarter of 2025 as they explore additional applications of their proprietary MSC-S platform in ocular diseases.
Read more →KALAPhases
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update -- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 -- -- Exploring opp
KALA BIO, Inc. has reported its financial results for Q4 and full-year 2023, alongside an update regarding its clinical programs. The company is advancing its Phase 2b CHASE trial of KPI-012 for treating persistent corneal epithelial defects (PCED), with topline data expected by the end of 2024. KALA's cash position is projected to fund operations into the third quarter of 2025, aided by recent private placements. Furthermore, KALA is exploring the potential expansion of KPI-012 for additional corneal conditions, potentially broadening its market impact.
Read more →KALAConferences/Events
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
KALA BIO, Inc. has announced that its CEO, Mark Iwicki, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference on March 4, 2024. The company is focused on developing innovative therapies for rare and severe eye diseases and is currently advancing its lead product, KPI-012, in clinical trials. KALA has received Orphan Drug and Fast Track designations from the FDA for KPI-012, indicating its commitment to addressing unmet medical needs in this space. Additionally, the management team will be available for one-on-one meetings during the conference to discuss their initiatives further.
Read more →KALAConferences/Events
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
KALA BIO, Inc. will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference in February 2024, showcasing its commitment to innovative therapies for rare eye diseases. The presentation will be available virtually as a pre-recorded fireside chat starting on February 13, 2024, and KALA management will also engage in one-on-one meetings during the conference. The company is currently developing its lead product, KPI-012, for the treatment of persistent corneal epithelial defect and exploring its use for other eye conditions.
Read more →KALAGeneral
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALA BIO, Inc. has announced the grant of non-statutory stock options to a new employee, totaling 3,125 shares. This inducement award aligns with Nasdaq Listing Rule 5635(c)(4) and aims to enhance talent acquisition. The stock options have an exercise price of $7.85 per share and will vest over a period of four years. KALA continues its focus on developing innovative therapies for severe eye diseases, with its lead candidate currently in clinical development.
Read more →KALAPhases
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update -- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 - -- As of
KALA BIO reported its third quarter financial results for 2023, highlighting active enrollment in its CHASE Phase 2b clinical trial for KPI-012 targeted at persistent corneal epithelial defect (PCED). The company anticipates topline data to be reported in the second half of 2024. As of September 30, 2023, KALA has $56.1 million in cash, enough to fund operations into the second quarter of 2025. However, the company experienced a decrease in cash from the previous year and reported significant losses in its operations.
Read more →KALAConferences/Events
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
KALA BIO, Inc. will present at the H.C. Wainwright 25th Annual Global Investment Conference, offering insights into its innovative therapies for severe eye diseases. A pre-recorded presentation will be accessible starting September 11, 2023. Management will engage in one-on-one meetings, highlighting their focus on advancing treatments like KPI-012, aimed at addressing corneal healing issues. The company is also exploring potential applications for retinal degenerative diseases.
Read more →KALAPhases
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update -- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024
KALA BIO, Inc. reported its Q2 2023 financial results and outlined advancements in its KPI-012 program for persistent corneal epithelial defect (PCED). The firm has secured a $15 million grant from the California Institute for Regenerative Medicine to support its clinical trial endeavors. The company is currently enrolling patients for its Phase 2b trial and anticipates topline data in the second quarter of 2024. KALA's financial status allows for operations through Q2 2025, despite a recent decline in cash reserves from last year.
Read more →KALAConferences/Events
KALA BIO to Participate in Upcoming Investor Conferences in August
KALA BIO, Inc. has announced its participation in several upcoming investor conferences in August 2023, including the Wedbush PacGrow Healthcare Conference and H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference. The company's management will be available for one-on-one investor meetings and a pre-recorded presentation will be made accessible through its website. KALA BIO is focused on developing therapies for rare ocular diseases, with its lead candidate, KPI-012, currently in clinical development for persistent corneal epithelial defect.
Read more →KALAGeneral
Kala Pharmaceuticals Announces Name Change to KALA BIO
Kala Pharmaceuticals announced its name change to KALA BIO, effective August 2, 2023, to better reflect its commitment to advancing biologics for ocular diseases. The company's MSC-S platform demonstrates potential for innovative therapies, with the lead candidate KPI-012 currently in Phase 2b trials for persistent corneal epithelial defect. KALA BIO is also exploring additional indications including Limbal Stem Cell Deficiency and retinal degenerative diseases. This rebranding aims to highlight the company's dedication to unique biologics in eye disease management.
Read more →KALAGeneral
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update -- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary sa
Kala Pharmaceuticals reported its first quarter 2023 financial results alongside a corporate update. The company announced positive safety data from the initial portion of the CHASE Phase 2b clinical trial for KPI-012, which is now advancing into primary efficacy phases. They have also received FDA Fast Track designation for KPI-012 as a treatment for persistent corneal epithelial defect (PCED) and secured a $15 million grant from the CIRM. The firm emphasized its commitment to expanding research opportunities and targeting topline data in the first quarter of 2024.
Read more →KALAPhases
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update -- Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targete
Kala Pharmaceuticals reported its fourth quarter and full-year financial results for 2022 and highlighted significant corporate developments. The company has enrolled the first patient in its CHASE Phase 2b clinical trial for KPI-012, aiming to address persistent corneal epithelial defect (PCED), with top-line data expected in the first quarter of 2024. Additionally, Kala closed a $31 million private placement financing, extending its cash runway through 2025. This financial boost will enable the company to advance its innovative therapies for rare ocular diseases.
Read more →KALAPhases
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update -- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 --
-- Ended Quarter with $52.4 million
Read more →KALAGeneral
Kala Pharmaceuticals Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on
Kala Pharmaceuticals Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022
ARLINGTON, Mass., October 20, 2022 -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company d
Read more →KALAGeneral
Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to
Holders of its Common Stock
ARLINGTON, Mass., Aug. 18, 2022 -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the research, de
Read more →KALAPhases
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update -- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Exp
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 --
-- Received $60M Upfront Payment from
Read more →KALAGeneral
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update - Expanded Coverage for EYSUVIS to 92% of Total Commercial Lives and 30% of All Medicare Lives - - Achieved 18% EYSUVIS Prescription Growth
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update
- Expanded Coverage for EYSUVIS to 92% of Total Commercial Lives and 30% of All Medicare Lives -
- Achieved 18% EYSUVIS Prescription Growth in 1Q 2022 -
- Presented KPI-012 Phase 1b Clinical Data a
Read more →KALAGeneral
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update -- Achieved $11.2 Million in Net Revenue in 2021 -- -- Expanded Coverage for EYSUVIS to 118 Million Commercia
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-- Achieved $11.2 Million in Net Revenue in 2021 --
-- Expanded Coverage for EYSUVIS to 118 Million Commercial Lives and 7.1 Million Medicare Lives --
-- KPI-012 Phas
Read more →KALAGeneral
Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing --
-- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial --
-- Ka
Read more →KALAGeneral
Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update -- Achieved $3.1 Million in Net Revenue in 3Q 2021 -- -- EYSUVIS Prescriptions Increased by 19% Compared to 2Q 2021 -- Expan
Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-- Achieved $3.1 Million in Net Revenue in 3Q 2021 --
-- EYSUVIS Prescriptions Increased by 19% Compared to 2Q 2021
-- Expanding Clinical-Stage Pipeline Through Acquisition of Comba
Read more →KALAGeneral
Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update -- EYSUVIS Prescriptions Increased by 93% Compared to First Quarter of 2021 -- -- Further Expanded Commercial Coverage for
Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-- EYSUVIS Prescriptions Increased by 93% Compared to First Quarter of 2021 --
-- Further Expanded Commercial Coverage for EYSUVIS to More Than 96 Million Lives --
-- Achieved $3.1
Read more →KALAGeneral
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update -- Achieved $3.3 Million in Net Revenue in First Quarter -- -- Launched EYSUVIS and Expanded Commercial Coverage to More tha
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
-- Achieved $3.3 Million in Net Revenue in First Quarter --
-- Launched EYSUVIS and Expanded Commercial Coverage to More than 69 Million Commercial Lives --
-- New Credit Facility P
Read more →KALAFDA Updates
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update -- Launched EYSUVIS , First and Only Prescription Therapy Approved Specifically for Short-Term Treatment of t
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
-- Launched EYSUVIS , First and Only Prescription Therapy Approved Specifically for Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease --
-- Progressing
Read more →KALAFDA Updates
Kala Pharmaceuticals Announces Availability of EYSUVIS TM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline -- First and only prescription therapy approved specifically for short-term treat
Kala Pharmaceuticals Announces Availability of EYSUVISTM for the
Treatment of Dry Eye Disease and Provides Update on Development
-- First and only prescription therapy approved specifically for short-term treatment of the signs and symptoms of dry eye disease now available in p
Read more →KALAFDA Updates
Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update -- Obtained FDA Approval for EYSUVIS TM , First Prescription Therapy Approved Specifically for the Short-Term Treatment of t
Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
-- Obtained FDA Approval for EYSUVISTM, First Prescription Therapy Approved Specifically for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease --
-- EYSUVIS Expec
Read more →KALAFDA Updates
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease -- First Approved Prescription Therapy Specifically for Short-Term Treatment of Dry Eye Dis
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
-- First Approved Prescription Therapy Specifically for Short-Term Treatment of Dry Eye Disease --
-- First Ocular Corticosteroid Indicated for Dry E
Read more →KALAFDA Updates
Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update - EYSUVIS TM NDA Accepted by FDA; Assigned PDUFA Goal Date of
Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
- EYSUVISTM NDA Accepted by FDA; Assigned PDUFA Goal Date of October 30, 2020 -
- 2Q 2020 INVELTYS Revenue of $0.8 Million -
- Conference Call and Webcast at 8:00 a.m. ET -
WATERT
Read more →KALAGeneral
Kala Pharmaceuticals, Inc. 2017 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this 2017 Equity Incentive Plan (the " Plan ") of Kala Pharmaceuticals, Inc., a Delaware corporation (the " Company "), is to advance the in
Kala Pharmaceuticals, Inc.
2017 EQUITY INCENTIVE PLAN
The purpose of this 2017 Equity Incentive
Plan (the "Plan") of Kala Pharmaceuticals, Inc., a Delaware corporation (the "Company"),
is to advance the interests of the Company's stockholders by enhancing the Company's abilit
Read more →KALAPhases
Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update -- Announced Positive Results from STRIDE 3 Clinical Trial of EYSUVIS in March 2020, Demonstrating Statistically Significant
Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
-- Announced Positive Results from STRIDE 3 Clinical Trial of EYSUVIS in March 2020, Demonstrating Statistically Significant Results for Primary and Key Secondary Endpoints --
-- EYS
Read more →KALAGeneral
Kala Pharmaceuticals Announces Pricing of Public Offering of 16,000,000 Shares of Common Stock
Kala Pharmaceuticals Announces Pricing
of Public Offering of 16,000,000 Shares of Common Stock
WATERTOWN, Mass - March 10, 2020 -
Kala Pharmaceuticals, Inc. ("Kala") (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development
and commercialization of inno
Read more →KALAPhases
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results – Completed Last Patient Last Visit for STRIDE 3 Dry Eye Disease Trial; Topline Results on Track for First Quarter of 2020 –
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Completed Last Patient Last Visit for STRIDE 3 Dry Eye Disease Trial; Topline Results on Track for First Quarter of 2020
Achieved Full Year 2019 INVELTYS Revenues of $6.1 Million
Conference Call a
Read more →KALAGeneral
NOT FOR PROMOTIONAL USE Key Highlights 3 Proprietary AMPPLIFY drug delivery technology to enhance delivery to target tissues of the eye IP protection for AMPPLIFY technology and products through 2033 AMPPLIFY TM Technolo
NOT FOR PROMOTIONAL USE Key Highlights 3 Proprietary AMPPLIFY drug delivery technology to enhance delivery to target tissues of the eye IP protection for AMPPLIFY technology and products through 2033 AMPPLIFY TM Technology Approved by FDA in August 2018 with U.S. launch in Januar
Read more →KALAConferences/Events
Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results –Conference Call and Webcast Today at 8:00 a.m. ET– WATERTOWN, Mass — (BUSINESS WIRE) — Kala Pharmaceuticals, Inc. (Kala) (NAS
Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results
Conference Call and Webcast Today at 8:00 a.m. ET
WATERTOWN, Mass (BUSINESS WIRE) Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of t
Read more →KALAFDA Updates
Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial Targeting Topline Data from STRIDE 3 by the End of 2019
Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial
Targeting Topline Data from STRIDE 3 by the End of 2019
WATERTOWN, Mass., August 8, 2019 Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced
Read more →KALAConferences/Events
Kala Pharmaceuticals Reports Second Quarter 2019 Financial Results –Conference Call and Webcast Today at 8:00 a.m. ET–
Kala Pharmaceuticals Reports Second Quarter 2019 Financial Results
Conference Call and Webcast Today at 8:00 a.m. ET
WATERTOWN, Mass, August 6, 2019 Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of
Read more →KALAConferences/Events
Kala Pharmaceuticals Reports First Quarter 2019 Financial Results –Conference Call and Webcast Today at 8:00 a.m. ET–
Kala Pharmaceuticals Reports First Quarter 2019 Financial Results
Conference Call and Webcast Today at 8:00 a.m. ET
WATERTOWN, Mass, May 9, 2019 Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of ther
Read more →KALAGeneral
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results · INVELTYS TM launched in January 2019 for the treatment of post-operative inflammation and pain following ocular surgery ·
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
Conference Call and Webcast Today at 4:30 p.m. ET
WATERTOWN, Mass, March 11, 2019 Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commerc
Read more →KALAGeneral
Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results – INVELTYS TM Launch on Track for Early 2019 – – Strengthened Cash Position; Runway Extends At Least Through Early 2020 – 
Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results
INVELTYSTM Launch on Track for Early 2019
Strengthened Cash Position; Runway Extends At Least Through Early 2020
KPI-121 0.25% NDA Filed for Dry Eye Disease
WALTHAM, Mass. --(BUSINESS WIRE)- November 8, 2018 Ka
Read more →KALAGeneral
Kala Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares WALTHAM, Mass –
Kala Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass October 11, 2018 Kala Pharmaceuticals, Inc. ( Kala ) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using
Read more →KALAGeneral
Kala Pharmaceuticals Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock
Kala Pharmaceuticals Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock
WALTHAM, Mass October 3, 2018 Kala Pharmaceuticals, Inc. ( Kala ) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its p
Read more →KALAFDA Updates
Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million - Financing provides support for NDA filing of KPI-121 0.25%, INVELTYS launch, and topline results for the STRIDE-3 trial of
Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million
- Financing provides support for NDA filing of KPI-121 0.25%, INVELTYS launch, and topline results for the STRIDE-3 trial of KPI-121 0.25% -
- Initial $75 million tranche funded imme
Read more →KALAGeneral
Risk Factors Kala Pharmaceuticals, Inc. ( we , us or our ) is filing information for the purpose of updating and superseding the risk factor disclosure contained in its prior public filings, including those previously se
Kala Pharmaceuticals, Inc. ( we , us or our ) is filing information for the purpose of updating and superseding the risk factor disclosure contained in its prior public filings, including those previously set forth in Part II, Item IA, Risk Factors of its Annual Report on Form 10
Read more →KALAFDA Updates
Kala Pharmaceuticals Announces FDA Approval of INVELTYS TM for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery First Twice-Daily Ocular Corticosteroid Indicated for the Treatment of Post-Op
Kala Pharmaceuticals Announces FDA Approval of INVELTYSTM for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
First Twice-Daily Ocular Corticosteroid Indicated for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
Kala
Read more →KALAFDA Updates
Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results – PDUFA Target Action Date for INVELTYS™ is
Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results
PDUFA Target Action Date for INVELTYS is August 24, 2018
Defined Strategy for KPI-121 0.25% in Dry Eye Disease
Strengthened Commercial Team in Preparation for INVELTYS Launch
WALTHAM, Mass.--(BUSINESS WIRE) Au
Read more →KALAGeneral
Kala Pharmaceuticals Reports First Quarter 2018 Financial Results WALTHAM, MA –
Kala Pharmaceuticals Reports First Quarter 2018 Financial Results
WALTHAM, MA May 10, 2018 Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particl
Read more →KALAFDA Updates
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results -- Update on dry eye clinical data -- -- PDUFA target action date for INVELTYS TM is
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
-- Update on dry eye clinical data --
-- PDUFA target action date for INVELTYSTM is August 24, 2018 --
-- Business update call at 8:00 AM ET today --
WALTHAM, MA March 26, 2018 Kala Pharmaceutica
Read more →KALAPhases
Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease Statistical significance achieved for the primary sign endpoint, conjunctival hyperemia at
Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease
Statistical significance achieved for the primary sign endpoint, conjunctival hyperemia at Day 15 in the ITT population, in STRIDE 1 (p<0.0001)
Stat
Read more →KALAConferences/Events
Innovation In Ophthalmology Corporate Overview January 2018 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that i
Innovation In Ophthalmology Corporate Overview January 2018
Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties including statem
Read more →KALAGeneral
Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update Completed Initial Public Offering Raising $103.5 million in gross proceeds Submitted New Drug Application to U.S. Food and Dr
Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update
Completed Initial Public Offering Raising $103.5 million in gross proceeds
Submitted New Drug Application to U.S. Food and Drug Administration for INVELTYSTM (KPI-121 1%)
WALTHAM, Ma
Read more →